Expertise
-
Practice Areas:
- Bar Admissions:
- Education:
- McGill University (1999) BCL/LLB
- Tufts University (1995) BA
Details
- Bio
- Cases
- Associations
- Blog Posts
- News & Media
- Publications & Presentations
- Recognition
Jordana Sanft (she/her)
is a partner at Lenczner Slaght.
Jordana practices in all areas of intellectual property law, and is particularly well known for her experience in patent and trademark disputes. She is recognized for treating clients as partners, providing practical and strategic advice and obtaining successful results in and out of the courtroom.
Jordana has particular expertise in the pharmaceutical and life sciences industry. She also works with clients in the technology, biotechnology, consumer goods, energy, food and beverage, hospitality, and horticulture industries. She regularly acts in proceedings under the Patented Medicines (Notice of Compliance) Regulations, patent impeachment and infringement actions, judicial review proceedings, and damages actions.
As part of her approach in leading Canadian IP litigation, Jordana works with clients to maximize success on a local and global level. Jordana has an interest in legal issues at the intersection of IP and artificial intelligence. She regularly works with clients concerning the protection and optimization of their intellectual property portfolios and enforcement of their intellectual property rights.
Jordana has appeared as counsel in matters before the Federal Court of Appeal, the Federal Court, the Ontario Superior Court of Justice, and specialized tribunals such as the Trademarks Opposition Board. Jordana is a registered patent and trademark agent.
-
Merck Canada Inc. v The Minister of Health
Counsel to Merck Canada Inc. in a judicial review proceeding in the Federal Court in regards to patent listing for KEYTRUDA. (Prior to joining Lenczner Slaght.)
-
Natco Pharma (Canada) Inc. v Canada (Health)
Counsel to Gilead Sciences Inc. in a judicial review proceeding in the Federal Court, which was the first ever challenge of data protection for anti-HIV combination drug therapies in respect of DESCOVY. Successfully upheld data protection. (Prior to joining Lenczner Slaght.)
-
Genentech Inc. et al v Amgen Canada Inc.
Counsel to Hoffmann-La Roche Limited and Genentech, Inc. in various Federal Court actions under the new PMNOC Regulations in respect of trastuzumab (HERCEPTIN), which were the first actions under the new regime. (Prior to joining Lenczner Slaght.)
-
Genentech Inc. et al v Celltrion Healthcare Co, Ltd.
Counsel to Hoffmann-La Roche Limited and Genentech, Inc. in various Federal Court actions under the new PMNOC Regulations in respect of trastuzumab (HERCEPTIN), which were the first actions under the new regime. (Prior to joining Lenczner Slaght.)
-
Eli Lilly v Various Generic Companies
Counsel to Eli Lilly and Company in various Federal Court proceedings in respect of teriparatide (FORTEO). (Prior to joining Lenczner Slaght.)
-
Hoffmann-La Roche Limited and Genentech, Inc. v Various Biosimilar and Generic Companies
Counsel to Hoffmann-La Roche Limited and Genentech, Inc. in various Federal Court proceedings in respect of bevacizumab (AVASTIN). (Prior to joining Lenczner Slaght.)
-
Gilead Sciences Inc. v Idenix Pharmaceuticals Inc.
Counsel to Gilead Sciences Inc in the Federal Court proceeding in respect of sofosbuvir, successfully invalidating Idenix’s ‘191 patent and maintaining Gilead’s ‘657 patent. (Prior to joining Lenczner Slaght.)
-
Apotex Inc v Pfizer Canada Inc
Counsel to Pfizer in a summary judgment motion regarding latanoprost (XALATAN), successfully upholding the validity of Pfizer’s ‘132 patent on summary judgment. (Prior to joining Lenczner Slaght.)
-
Glaxosmithkline Inc. et al v. Pharmascience Inc. et al
Counsel to Glaxosmithkline Inc. in various proceedings in the Federal Court including regarding valacyclovir hydrochloride (VALTREX). (Prior to joining Lenczner Slaght.)
-
Fairmont Hotels Re Trademark Matters
Counsel to Fairmont Hotels in various trademark prosecution and litigation matters, including litigation matters to protect company trademarks and corporate name in the Federal Court, Opposition Board and pursuant to the Canada Business Corporations Act. (Prior to joining Lenczner Slaght.)
-
Intellectual Property Institute of Canada - Conference Committee Chair (2021-2023); Vice Chair (2019-2021); Women in IP Networking Group
-
Canadian Bar Association - Intellectual Property Section; IP Court Practice Committee - Chair (2017-2020) and Member (2021)
-
International Association for the Protection of Intellectual Property
-
The Toronto Intellectual Property Group
-
ChIPs - Non-profit organization advancing women in technology, law and policy
-
The York School - Risk Committee of the Board of Directors; Member at Large (2017-present)
-
Youth Rising Above - Board Member (2021-2022)
-
2021 Year in Review & 2022 Trends to Watch: Pharmaceutical Patents
In 2021, the Canadian pharmaceutical and life sciences industries were once again at the forefront of innovation, developing and commercializing new vaccines, drugs, and medical devices. The media continued to shine a light on the advances made to protect the public from COVID-19, including regulatory approvals for new mRNA and adenovirus vector vaccines. In the pharmaceutical patent litigation arena in particular, we saw some new trends develop. There were important developments in proceedings relating to pharmaceutical patents, advances in cases and legislative developments relating to the Patented Medicine Prices Review Board (“PMPRB”) as well as judicial review applications and appeals in patent-related fields.
-
New IP Partner Joins Lenczner Slaght
Canada’s leading litigation firm is proud to welcome exceptional intellectual property litigator, Jordana Sanft, as a strong new addition to its formidable IP team.
-
Intellectual Property Strategy for AI Technology in Canada
Jordana Sanft co-authored the article Intellectual Property Strategy for AI Technology in Canada, which was published in "Leading Legal Disruption: Artificial Intelligence and a Toolkit for Lawyers and the Law" by Thomson Reuters. (Prior to joining Lenczner Slaght)
-
Maximizing the Expert Witness in Civil Litigation
Jordana Sanft shared her expertise at the OBA's Civil Litigation program titled "Maximizing the Expert Witness in Civil Litigation". She presented on the panel Strengthening Expert Evidence in Court - Compelling Chief/Cross Strategies. (Prior to joining Lenczner Slaght)
-
Jordana Sanft shared her expertise at the University of Toronto's 8th Annual Patent Colloquium. Jordana spoke on the panel Recent Trends in Patent Infringement: Indirect Infringement. (Prior to joining Lenczner Slaght)
-
Artificial Intelligence and Intellectual Property Considerations
Jordana Sanft co-authored the article Artificial Intelligence and Intellectual Property Considerations, which was published in the 2018 issue of Financier Worldwide.
-
Mastering Winning Discovery Techniques
Jordana Sanft presented at The Advocates' Society's "Mastering Winning Discovery Techniques" program. Jordana shared her expert insights on Conducting a Discovery and Implications for Trial. (Prior to joining Lenczner Slaght)
-
The Law of Utility in Canada - Where Are We Now and Where Are We Going
Jordana Sanft led a discussion on The Law of Utility in Canada - Where Are We Now and Where Are We Going at the Intellectual Property Institute of Canada's 2017 Annual General Meeting. (Prior to joining Lenczner Slaght)
-
Jordana Sanft was invited to speak at the Canadian Bar Association's 2017 IP Day on The Dos and Don'ts of Appeals. (Prior to joining Lenczner Slaght)
-
Chambers Global (2020-2021)
Intellectual Property – Litigation (Canada)
-
Chambers Canada (2020-2022)
Intellectual Property: Litigation (Nationwide – Canada), Life Sciences: IP/Patent Litigation (Nationwide – Canada)
-
Canadian Legal Lexpert® Directory (2018-2021)
Intellectual Property (Repeatedly Recommended), Litigation - Intellectual Property (Consistently Recommended)
-
Lexpert Special Edition: Canada's Leading Technology Lawyers (2021)
-
Lexpert Special Edition: Canada's Leading Health Sciences Lawyers (2021)
-
Best Lawyers in Canada (2015-2022)
-
IAM Patent 1000 (2019-2020)
Patent Litigation: Recommended Individual (Silver)
-
LMG Life Sciences (2016)
Canadian IP Contentious Impact Case of the Year (Gilead Sciences Inc v Idenix Pharmaceuticals Inc)
-
LMG Life Sciences (2021)
Canadian Patent Impact Case of the Year (Natco Pharma v Minister of Health and Gilead Sciences)
-
Managing Intellectual Property: IP STARS (2015-2021)
Patent Star – Canada, Trademark Star – Canada, Top 250 Women in IP
Show more